fluconazole has been researched along with Vulvovaginitis in 12 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Vulvovaginitis: Inflammation of the VULVA and the VAGINA, characterized by discharge, burning, and PRURITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic and recurrent vulvovaginitis, however, does not respond to this standard experimental therapy; therefore, the study presented in this article investigated the effect of common antifungal drugs (amphotericin B [AMB], fluconazole [FLU], and itraconazole [ITC]), in combination with 2-phenylethanol, on the Candida species isolated from cases of chronic and recurrent vulvovaginitis, thereby allowing the recommendation of a more appropriate treatment option." | 7.88 | Effect of 2-Phenylethanol as Antifungal Agent and Common Antifungals (Amphotericin B, Fluconazole, and Itraconazole) on Candida Species Isolated from Chronic and Recurrent Cases of Candidal Vulvovaginitis. ( Ashrafi-Khozani, M; Falahati, M; Farahyar, S; Heidarie-Kohan, F; Majdabadi, N; Mohammadnejad, S; Rahimi-Moghaddam, P; Razavi, T, 2018) |
| "To determine if failure of recurrent Candida albicans vulvovaginitis to respond clinically to fluconazole is related to in vitro mycologic resistance." | 7.72 | Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance. ( Carey, JC; MacNeill, C; Weisz, J, 2003) |
| " Previous in vitro data suggest that, in combination with certain antifungals, farnesol may have an adjuvant anti-biofilm agent." | 5.43 | The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. ( Bozó, A; Domán, M; Kardos, G; Kovács, R; Majoros, L; Varga, I, 2016) |
| " Chronic and recurrent vulvovaginitis, however, does not respond to this standard experimental therapy; therefore, the study presented in this article investigated the effect of common antifungal drugs (amphotericin B [AMB], fluconazole [FLU], and itraconazole [ITC]), in combination with 2-phenylethanol, on the Candida species isolated from cases of chronic and recurrent vulvovaginitis, thereby allowing the recommendation of a more appropriate treatment option." | 3.88 | Effect of 2-Phenylethanol as Antifungal Agent and Common Antifungals (Amphotericin B, Fluconazole, and Itraconazole) on Candida Species Isolated from Chronic and Recurrent Cases of Candidal Vulvovaginitis. ( Ashrafi-Khozani, M; Falahati, M; Farahyar, S; Heidarie-Kohan, F; Majdabadi, N; Mohammadnejad, S; Rahimi-Moghaddam, P; Razavi, T, 2018) |
| "To determine if failure of recurrent Candida albicans vulvovaginitis to respond clinically to fluconazole is related to in vitro mycologic resistance." | 3.72 | Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance. ( Carey, JC; MacNeill, C; Weisz, J, 2003) |
| " Previous in vitro data suggest that, in combination with certain antifungals, farnesol may have an adjuvant anti-biofilm agent." | 1.43 | The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. ( Bozó, A; Domán, M; Kardos, G; Kovács, R; Majoros, L; Varga, I, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sobel, JD | 1 |
| Majdabadi, N | 1 |
| Falahati, M | 1 |
| Heidarie-Kohan, F | 1 |
| Farahyar, S | 1 |
| Rahimi-Moghaddam, P | 1 |
| Ashrafi-Khozani, M | 1 |
| Razavi, T | 1 |
| Mohammadnejad, S | 1 |
| Kolekar, K | 1 |
| Tambe, S | 1 |
| Aderao, R | 1 |
| Nayak, C | 1 |
| Bozó, A | 1 |
| Domán, M | 1 |
| Majoros, L | 1 |
| Kardos, G | 1 |
| Varga, I | 1 |
| Kovács, R | 1 |
| Savini, V | 2 |
| Catavitello, C | 2 |
| Bianco, A | 1 |
| Balbinot, A | 2 |
| D'Antonio, F | 2 |
| D'Antonio, D | 2 |
| Dorrell, L | 1 |
| Edwards, A | 1 |
| MacNeill, C | 1 |
| Weisz, J | 1 |
| Carey, JC | 1 |
| Eschenbach, DA | 1 |
| Buscemi, L | 1 |
| Arechavala, A | 1 |
| Negroni, R | 1 |
| Mohanty, S | 1 |
| Xess, I | 1 |
| Hasan, F | 1 |
| Kapil, A | 1 |
| Mittal, S | 1 |
| Tolosa, JE | 1 |
| Manna, A | 1 |
| Talia, M | 1 |
| Febbo, F | 1 |
| Di Bonaventura, G | 1 |
| Celentano, C | 1 |
| Liberati, M | 1 |
| Piccolomini, R | 1 |
| Rowe, BR | 1 |
| Thorpe, J | 1 |
| Barnett, A | 1 |
1 review available for fluconazole and Vulvovaginitis
| Article | Year |
|---|---|
Two cases of vaginitis caused by itraconazole-resistant Saccharomyces cerevisiae and a review of recently published studies.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Diagnosis, Differential; Drug Resistance, Funga | 2008 |
1 trial available for fluconazole and Vulvovaginitis
| Article | Year |
|---|---|
Safety of fluconazole in women taking oral hypoglycaemic agents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Blood Glucose; Clotrimazole; Diabetes Mellitus; Drug | 1992 |
10 other studies available for fluconazole and Vulvovaginitis
| Article | Year |
|---|---|
Resistance to Fluconazole of Candida albicans in Vaginal Isolates: a 10-Year Study in a Clinical Referral Center.
Topics: Antifungal Agents; Candida albicans; Drug Resistance, Fungal; Female; Fluconazole; Humans; Microbial | 2023 |
Effect of 2-Phenylethanol as Antifungal Agent and Common Antifungals (Amphotericin B, Fluconazole, and Itraconazole) on Candida Species Isolated from Chronic and Recurrent Cases of Candidal Vulvovaginitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida; Chronic Disease; Dose-Response Relationship, Drug | 2018 |
Chronic vulvovaginitis caused by Candida dubliniensis in an immunologically competent adult female.
Topics: Adult; Antifungal Agents; Candida; Female; Fluconazole; Humans; Linezolid; Treatment Outcome; Vulvov | 2019 |
The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.
Topics: Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Disease Models, Animal; Drug Re | 2016 |
Azole resistant Candida glabrata vulvovaginitis treated with boric acid.
Topics: Adult; Antifungal Agents; Boric Acids; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Femal | 2009 |
Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; H | 2002 |
Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance.
Topics: Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis; Cohort Studies; Drug Resistance | 2003 |
Chronic vulvovaginal candidiasis.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disease; Drug Administra | 2004 |
[Study of acute vulvovaginitis in sexually active adult women, with special reference to candidosis, in patients of the Francisco J. Muñiz Infectious Diseases Hospital].
Topics: Acute Disease; Adolescent; Adult; Argentina; Candida; Candidiasis, Vulvovaginal; Carrier State; Como | 2004 |
Prevalence & susceptibility to fluconazole of Candida species causing vulvovaginitis.
Topics: Candida; Dose-Response Relationship, Drug; Female; Fluconazole; Humans; India; Species Specificity; | 2007 |